Weir Robin A P
Department of Cardiology, University Hairmyres Hospital, Glasgow, United Kingdom,
Cardiology. 2019;142(1):4-6. doi: 10.1159/000497071. Epub 2019 Mar 8.
The uptake of sacubitril/valsartan since the PARADIGM study confirmed its beneficial effects on outcomes over enalapril in chronic systolic heart failure has inevitably led to potential interactions with co-prescribed medications in real-world patients. We report two cases that raise the possibility of an interaction between sacubitril/valsartan and the class Ib anti-arrhythmic mexiletine resulting in proarrhythmic effects. We discuss the pharmacokinetics of both agents and posit potential mechanistic interactions that suggest caution should be used and careful monitoring for (ventricular) arrhythmias applied in patients receiving sacubitril/valsartan and mexiletine.
自PARADIGM研究证实沙库巴曲缬沙坦在慢性收缩性心力衰竭患者中比依那普利更能改善预后以来,其应用不可避免地导致了在真实世界患者中与联合使用的药物发生潜在相互作用。我们报告了两例病例,提示沙库巴曲缬沙坦与Ib类抗心律失常药物美西律之间可能存在相互作用,从而导致促心律失常效应。我们讨论了这两种药物的药代动力学,并提出了潜在的机制性相互作用,表明在接受沙库巴曲缬沙坦和美西律治疗的患者中应用时应谨慎,并密切监测(室性)心律失常。